Diagnosis and treatment of paraneoplastic neurological disorders.
In about two thirds of cases, patients with paraneoplastic neurological disorders present to the neurologist without a known tumor. Due to the ongoing immune response, this tumor tends to stay biologically relatively benign, and therefore difficult to diagnose. In patients with a known tumor, the neurological symptoms often precede a tumor recurrence. In both scenarios, anti-neuronal antibodies are an invaluable diagnostic help to the clinician, and may be supplemented by other diagnostic tests such as MRI, CSF, and electrophysiology. Tumor therapy remains the mainstay of therapeutic options, although early immune therapy must be started in parallel. It is hoped that the recent fundamental advances in understanding the autoimmune pathology of these disorders, especially the role of cytotoxic T cells, will eventually lead to more effective treatment options.
Voltz
R
R
Institute of Clinical Neuroimmunology and Department of Neurology, Klinikum Grosshadern, München, Germany. rvoltz@nro.med.uni-muenchen.de
Graus
F
F
D000906:Antibodies / Q000276:immunology; D003937:Diagnosis, Differential; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009422:Nervous System Diseases; D009474:Neurons / Q000276:immunology; D020364:Paraneoplastic Polyneuropathy / Q000145:classification / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D010346:Patient Care Management / Q000379:methods*
D000906:Antibodies